-DOCSTART- -X- O
The -X- _ O
devastation -X- _ O
caused -X- _ O
by -X- _ O
the -X- _ O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
EVD -X- _ I-Patient
) -X- _ I-Patient
outbreak -X- _ I-Patient
in -X- _ I-Patient
West -X- _ I-Patient
Africa -X- _ I-Patient
has -X- _ O
brought -X- _ O
to -X- _ O
the -X- _ O
fore -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
important -X- _ O
ethical -X- _ O
debates -X- _ O
about -X- _ O
how -X- _ O
best -X- _ O
to -X- _ O
respond -X- _ O
to -X- _ O
a -X- _ O
health -X- _ O
crisis. -X- _ O
These -X- _ O
debates -X- _ O
include -X- _ O
issues -X- _ O
related -X- _ O
to -X- _ O
prevention -X- _ O
and -X- _ O
containment -X- _ O
, -X- _ O
management -X- _ O
of -X- _ O
the -X- _ O
health -X- _ O
care -X- _ O
workforce -X- _ O
, -X- _ O
clinical -X- _ O
care -X- _ O
, -X- _ O
and -X- _ O
research -X- _ O
design -X- _ O
, -X- _ O
all -X- _ O
of -X- _ O
which -X- _ O
are -X- _ O
situated -X- _ O
within -X- _ O
the -X- _ O
overarching -X- _ O
moral -X- _ O
problem -X- _ O
of -X- _ O
severe -X- _ O
transnational -X- _ O
disadvantage -X- _ O
, -X- _ O
which -X- _ O
has -X- _ O
very -X- _ O
real -X- _ O
and -X- _ O
specific -X- _ O
impacts -X- _ O
upon -X- _ O
the -X- _ O
ability -X- _ O
of -X- _ O
citizens -X- _ O
of -X- _ O
EVD-affected -X- _ O
countries -X- _ O
to -X- _ O
respond -X- _ O
to -X- _ O
a -X- _ O
disease -X- _ O
outbreak. -X- _ O
Ethical -X- _ O
issues -X- _ O
related -X- _ O
to -X- _ O
prevention -X- _ O
and -X- _ O
containment -X- _ O
include -X- _ O
the -X- _ O
appropriateness -X- _ O
and -X- _ O
scope -X- _ O
of -X- _ O
quarantine -X- _ O
and -X- _ O
isolation -X- _ O
within -X- _ O
and -X- _ O
outside -X- _ O
affected -X- _ O
countries. -X- _ O
The -X- _ O
possibility -X- _ O
of -X- _ O
infection -X- _ O
in -X- _ O
health -X- _ O
care -X- _ O
workers -X- _ O
impelled -X- _ O
consideration -X- _ O
of -X- _ O
whether -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
obligation -X- _ O
to -X- _ O
provide -X- _ O
health -X- _ O
services -X- _ O
where -X- _ O
personal -X- _ O
protection -X- _ O
equipment -X- _ O
is -X- _ O
inadequate -X- _ O
, -X- _ O
alongside -X- _ O
the -X- _ O
issue -X- _ O
of -X- _ O
whether -X- _ O
the -X- _ O
health -X- _ O
care -X- _ O
workforce -X- _ O
should -X- _ O
have -X- _ O
special -X- _ O
access -X- _ O
to -X- _ O
experimental -X- _ O
treatment -X- _ O
and -X- _ O
care -X- _ O
interventions -X- _ O
under -X- _ O
development. -X- _ O
In -X- _ O
clinical -X- _ O
care -X- _ O
, -X- _ O
ethical -X- _ O
issues -X- _ O
include -X- _ O
the -X- _ O
standards -X- _ O
of -X- _ O
care -X- _ O
owed -X- _ O
to -X- _ O
people -X- _ O
who -X- _ O
comply -X- _ O
with -X- _ O
quarantine -X- _ O
and -X- _ O
isolation -X- _ O
restrictions. -X- _ O
Ethical -X- _ O
issues -X- _ O
in -X- _ O
research -X- _ O
include -X- _ O
appropriate -X- _ O
study -X- _ O
design -X- _ O
related -X- _ O
to -X- _ O
experimental -X- _ B-Intervention
vaccines -X- _ I-Intervention
and -X- _ I-Intervention
treatment -X- _ I-Intervention
interventions -X- _ I-Intervention
, -X- _ O
and -X- _ O
the -X- _ O
sharing -X- _ O
of -X- _ O
data -X- _ O
and -X- _ O
biospecimens -X- _ O
between -X- _ O
research -X- _ O
groups. -X- _ O
The -X- _ O
compassionate -X- _ B-Comparison
use -X- _ I-Comparison
of -X- _ I-Comparison
experimental -X- _ I-Comparison
drugs -X- _ I-Comparison
intersects -X- _ O
both -X- _ O
with -X- _ O
research -X- _ O
ethics -X- _ O
and -X- _ O
clinical -X- _ O
care. -X- _ O
The -X- _ O
role -X- _ O
of -X- _ O
developed -X- _ O
countries -X- _ O
also -X- _ O
came -X- _ O
under -X- _ O
scrutiny -X- _ O
, -X- _ O
and -X- _ O
we -X- _ O
concluded -X- _ O
that -X- _ O
developed -X- _ O
countries -X- _ O
have -X- _ O
an -X- _ O
obligation -X- _ O
to -X- _ O
contribute -X- _ O
to -X- _ O
the -X- _ O
containment -X- _ O
of -X- _ O
EVD -X- _ O
infection -X- _ O
by -X- _ O
contributing -X- _ O
to -X- _ O
the -X- _ O
strengthening -X- _ O
of -X- _ O
local -X- _ O
health -X- _ O
care -X- _ O
systems -X- _ O
and -X- _ O
infrastructure -X- _ O
in -X- _ O
an -X- _ O
effort -X- _ O
to -X- _ O
provide -X- _ O
fair -X- _ O
benefits -X- _ O
to -X- _ O
communities -X- _ O
engaged -X- _ O
in -X- _ O
research -X- _ O
, -X- _ O
ensuring -X- _ O
that -X- _ O
affected -X- _ O
countries -X- _ O
have -X- _ O
ready -X- _ O
and -X- _ O
affordable -X- _ O
access -X- _ O
to -X- _ O
any -X- _ O
therapeutic -X- _ O
or -X- _ O
preventative -X- _ B-Intervention
interventions -X- _ I-Intervention
developed -X- _ I-Intervention
, -X- _ O
and -X- _ O
supporting -X- _ O
affected -X- _ O
countries -X- _ O
on -X- _ O
their -X- _ O
way -X- _ O
to -X- _ O
recovery -X- _ O
from -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
EVD -X- _ O
on -X- _ O
their -X- _ O
social -X- _ O
and -X- _ O
economic -X- _ O
lives -X- _ O
. -X- _ O

